Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Brief Report: Respiratory Syncytial Virus Activity --- United States,
July 2006--November 2007
Respiratory syncytial virus (RSV), the most common cause of severe lower respiratory tract disease among infants
and young children, typically infects persons by age 2 years and can cause subsequent infections throughout life
(1). RSV infection primarily manifests as bronchiolitis or pneumonia and results in approximately 75,000 to
125,000 hospitalizations in the United States each year
(1). Persons at increased risk for severe disease or death include
premature infants, older adults, and persons of any age with compromised respiratory, cardiac, or immune systems
(2,3). RSV is transmitted from person to person via close contact, droplets, or fomites. In temperate climates, peak RSV
activity typically occurs during the winter. However, year-to-year national and regional variability in the RSV season onset
and offset* occurs in the United States (4). RSV circulation also varies by geographic location; for example, Florida has
an earlier season onset and a longer season than the rest of the United States
(5). Using data reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), this report summarizes RSV temporal and
geographic trends in the United States during the weeks ending July 8,
2006--June 30, 2007, and for the first 5 months of
the current reporting season (the weeks ending July 7--November 24, 2007). Appropriately timed diagnostic tests
can provide data that indicate when the RSV season begins nationally and regionally, information that has been critical
in determining when to begin RSV prophylaxis for infants and children at high risk for infection.
NREVSS receives weekly reports from a passive voluntary network of laboratories regarding the number of
specimens tested for specific viral pathogens, including RSV, and the number of positive results, stratified by test type. During
July 2006--June 2007, a total of 94 clinical and public health laboratories reported RSV data. Laboratories that
were included in this analysis met the following three criteria: reported
>30 weeks of data, tested >15 specimens per
week during the winter months, and reported
>2% of specimens testing positive annually. Sixty-three (67%)
laboratories representing 36 states met these criteria and reported a total of 126,617 RSV antigen-detection tests, of which
21,470
(17.0%) were positive. The national RSV season onset began during the week ending November 11, 2006,
and continued for 19 weeks until the season offset (week ending March 17, 2007).
Data were summarized by region (Midwest, South [excluding Florida], Northeast, and West); data from Florida
are presented separately because they differed substantially from RSV-detection data from the remainder of the South
(5) (Figure). The 2006--07 RSV season onset occurred during the week ending November 11, 2006, in the Midwest
(12 laboratories reporting); the week ending November 18 in the Northeast (eight laboratories reporting); and the
week ending December 16 in the West (14 laboratories reporting). The season offset occurred during the week
ending February 10, 2007, in the Northeast; the week ending March 17 in the Midwest; and the week ending March 31 in
the West. The RSV season onset in the South (excluding Florida) (27 laboratories reporting) began during the week
ending October 28, 2006, and continued until the week ending February 24, 2007 (18 weeks). The RSV season onset
in Florida (two Miami laboratories reporting) began during the week ending July 1, 2006, and continued until the
week ending January 27, 2007 (31 weeks).
For the 2007--08 season, the number of reporting laboratories and geographic coverage has increased substantially as
a result of a data-sharing agreement with Surveillance Data, Inc. (SDI), a private company that conducts
RSV surveillance.§ On the basis of preliminary reports from the week ending July 7, 2007, to the week ending November
24, a total of 179 laboratories in 46 states and the District of Columbia reported 69,230 RSV tests and 5,173
(7.5%) positive results by antigen detection to NREVSS. Reports received through November 24 indicate that although
the national RSV season onsethas not yet occurred, the
regional season onset occurred during the week
ending November 17 in the South (58 laboratories reporting,
excluding Florida) and during the week ending November 24
in the Northeast (23 laboratories reporting). As of
November 24, reports from the Midwest (48 laboratories reporting)
and West (37 laboratories reporting) did not indicate onset of the RSV season. Florida continued to have a unique
onset(week ending August 4 [13 laboratories
reporting]). Weekly updates indicating RSV national,
regional, and state trends are available from the NREVSS website
(6); data from Florida laboratories are available from the Florida Department
of Public health website (7).
No vaccine or effective therapy is available for RSV.
Infants and children at risk for severe RSV infection can
receive immune prophylaxis with monthly doses of a
humanized murine anti-RSV monoclonal antibody during the RSV
season (8). Specific immune prophylaxis guidelines are available from the American Academy of Pediatrics
(8,9).
Reported by:National Respiratory and Enteric Virus Surveillance System collaborating laboratories. CA Panozzo, MPH, AL Fowlkes,
MPH, E Schneider, MD, LJ Anderson, MD, Div of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
References
Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among U.S. children,
1980--1996. JAMA 1999;282:1440--6.
Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr
2003;143(5 Suppl):S112--17.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J
Med 2005;352:1749--59.
Mullins JA, LaMonte AC, Bresee JS, Anderson LJ. Substantial variability in community RSV season timing. Pediatr Infect Dis J 2003;22:857--62.
Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial
virus infections. Pediatrics 2003;112(6 Pt 1):1447--52.
American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 report of
the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics;
2006:560--6.
* As defined by NREVSS, RSV national and regional season onset is the first of 2 consecutive weeks during which the median percentage of specimens testing
positive for RSV antigen is >10%. RSV season offset is the last of 2 consecutive weeks during which the median percentage of positive specimens is
>10%.
Northeast: Connecticut, Massachusetts, New Hampshire, New Jersey, New York, and Rhode Island;
Midwest: Illinois, Indiana, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin;
South: Alabama, Arkansas, Delaware, District of Columbia, Georgia, Kentucky, Louisiana,
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, and Virginia;
West: Alaska, Arizona, California, Colorado, Hawaii,
Montana, Washington, and Wyoming; Florida.
§ SDI conducts RSV surveillance with support from MedImmune, Inc. (Gaithersburg, Maryland). In fall 2006, CDC and SDI signed a memorandum
of understanding to share RSV surveillance data to make the most complete RSV dataset available. The memorandum outlines the voluntary participation of
laboratories, type of data shared, frequency of reporting, and approval and acknowledgements for data publication. The relationship between CDC and SDI is limited to
data sharing, as outlined in the memorandum. CDC does not make recommendations regarding the administration of RSV immune prophylaxis. For
additional information, contact NREVSS by e-mail at nrevss@cdc.gov.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
